Literature DB >> 16210037

Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.

Anna Falanga1, Marina Marchetti, Tiziano Barbui, C Wayne Smith.   

Abstract

Thrombotic complications are frequently observed in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Abnormalities of red blood cells and platelets arising from the clonal rearrangement of hematopoietic cells have been considered, although causal relationships between any of these specific abnormalities and thrombosis have not been clearly established. The involvement of neutrophils and macrophages, which participate in thrombosis and hemostasis, has been insufficiently explored in PV and ET. Persistent activation of circulating neutrophils was recently demonstrated in ET and PV patients, in parallel with an increase in plasma concentrations of endothelial damage-derived and prothrombotic substances. Other studies have explored whether the augmentation of adhesion of neutrophils may affect neutrophil/platelet interaction since a significant increase in circulating neutrophil/platelet aggregates is found in ET and PV. This review summarizes the current knowledge of the pathogenesis of thrombosis in PV and ET, with emphasis on the role of neutrophils in hemostasis and their possible involvement in the mechanisms of the acquired thrombophilia of these patients. Available data suggest that these hemostatic markers deserve to be included in prospective clinical studies aimed at identifying their predictive role in the vascular complications of patients with ET and PV.

Entities:  

Mesh:

Year:  2005        PMID: 16210037     DOI: 10.1053/j.seminhematol.2005.05.023

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  18 in total

1.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

Authors:  Steffen Massberg; Lenka Grahl; Marie-Luise von Bruehl; Davit Manukyan; Susanne Pfeiler; Christian Goosmann; Volker Brinkmann; Michael Lorenz; Kiril Bidzhekov; Avinash B Khandagale; Ildiko Konrad; Elisabeth Kennerknecht; Katja Reges; Stefan Holdenrieder; Siegmund Braun; Christoph Reinhardt; Michael Spannagl; Klaus T Preissner; Bernd Engelmann
Journal:  Nat Med       Date:  2010-08-01       Impact factor: 53.440

2.  Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Authors:  Marina Marchetti; Carmen J Tartari; Laura Russo; Marina Panova-Noeva; Annamaria Leuzzi; Alessandro Rambaldi; Guido Finazzi; Barry Woodhams; Anna Falanga
Journal:  Am J Hematol       Date:  2013-11-20       Impact factor: 10.047

3.  Diagnosis and Management of Polycythemia Vera in a Ferret (Mustela putorius furo).

Authors:  Kim Le; Hugues Beaufrère; Laura L Bassel; Sarah Wills; Delphine Laniesse; Shauna L Blois; Dale A Smith
Journal:  Comp Med       Date:  2016-12-01       Impact factor: 0.982

4.  JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

Authors:  S Leah Etheridge; Michelle E Roh; Megan E Cosgrove; Veena Sangkhae; Norma E Fox; Junmei Chen; José A López; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

5.  Superior vena cava syndrome in a patient with polycytemia vera: diagnosis and treatment.

Authors:  Salvatore Lentini; Mario Barone; Filippo Benedetto; Francesco Spinelli
Journal:  Cardiol Res Pract       Date:  2010-06-03       Impact factor: 1.866

6.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Authors:  Leonardo Boiocchi; Umberto Gianelli; Alessandra Iurlo; Falko Fend; Irina Bonzheim; Daniele Cattaneo; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

Review 7.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

8.  JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.

Authors:  Margarida Coucelo; Gonçalo Caetano; Teresa Sevivas; Susana Almeida Santos; Teresa Fidalgo; Celeste Bento; Manuela Fortuna; Marta Duarte; Cristina Menezes; M Letícia Ribeiro
Journal:  Int J Hematol       Date:  2013-11-26       Impact factor: 2.490

9.  Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation.

Authors:  Margarita Hurtado-Nedelec; Marie-José Csillag-Grange; Tarek Boussetta; Sahra Amel Belambri; Michèle Fay; Bruno Cassinat; Marie-Anne Gougerot-Pocidalo; Pham My-Chan Dang; Jamel El-Benna
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

10.  Iloprost in COVID-19: The Rationale of Therapeutic Benefit.

Authors:  Paola Maria Faggioli; Nicola Mumoli; Antonino Mazzone
Journal:  Front Cardiovasc Med       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.